MX367460B - Anticuerpos biespecificos anti-baff-anti-il-17. - Google Patents
Anticuerpos biespecificos anti-baff-anti-il-17.Info
- Publication number
- MX367460B MX367460B MX2014012692A MX2014012692A MX367460B MX 367460 B MX367460 B MX 367460B MX 2014012692 A MX2014012692 A MX 2014012692A MX 2014012692 A MX2014012692 A MX 2014012692A MX 367460 B MX367460 B MX 367460B
- Authority
- MX
- Mexico
- Prior art keywords
- baff
- bispecific antibodies
- sjã
- gren
- sle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a anticuerpos biespecíficos que específicamente enlazan el Factor de Activación de células B de la Familia TNF (BAFF) e lnterleucina-17A (lL-17) y se caracterizan porque tienen alta afinidad y fuertes propiedades neutralizantes tanto para BAFF como IL-17. Se espera que los anticuerpos biespecíficos de la invención sean útiles en el tratamiento de Nefritis Lúpica (LN), Lupus Eritematoso Sistémico (SLE), Artritis Reumatoide (RA), Psoriasis (Ps), Espondilitis Anquilosante (AS), Artritis Psoriática (PA), Síndrome de Sjögren primario (pSS), o Mieloma Múltiple (MM).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636302P | 2012-04-20 | 2012-04-20 | |
US201361768747P | 2013-02-25 | 2013-02-25 | |
PCT/US2013/036677 WO2013158577A1 (en) | 2012-04-20 | 2013-04-16 | Anti-baff-anti-il-17 bispecific antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014012692A MX2014012692A (es) | 2015-01-22 |
MX367460B true MX367460B (es) | 2019-08-22 |
Family
ID=48539373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014012692A MX367460B (es) | 2012-04-20 | 2013-04-16 | Anticuerpos biespecificos anti-baff-anti-il-17. |
Country Status (40)
Country | Link |
---|---|
US (2) | US9359448B2 (es) |
EP (2) | EP2838920B1 (es) |
JP (1) | JP6216772B2 (es) |
KR (1) | KR101673735B1 (es) |
CN (1) | CN104220455B (es) |
AP (1) | AP2014008002A0 (es) |
AR (1) | AR090626A1 (es) |
AU (1) | AU2013249546B2 (es) |
BR (1) | BR112014025649A2 (es) |
CA (1) | CA2869148C (es) |
CL (1) | CL2014002616A1 (es) |
CO (1) | CO7160039A2 (es) |
CR (1) | CR20140466A (es) |
CY (1) | CY1118824T1 (es) |
DK (1) | DK2838920T3 (es) |
DO (1) | DOP2014000234A (es) |
EA (1) | EA029185B1 (es) |
EC (1) | ECSP14023405A (es) |
ES (2) | ES2621917T3 (es) |
GT (1) | GT201400217A (es) |
HK (1) | HK1201862A1 (es) |
HR (1) | HRP20170468T1 (es) |
HU (1) | HUE032153T2 (es) |
IL (1) | IL234965B (es) |
IN (1) | IN2014MN01876A (es) |
LT (1) | LT2838920T (es) |
ME (1) | ME02596B (es) |
MX (1) | MX367460B (es) |
MY (1) | MY173282A (es) |
NZ (1) | NZ630865A (es) |
PE (1) | PE20142147A1 (es) |
PH (1) | PH12014502333A1 (es) |
PL (1) | PL2838920T3 (es) |
PT (1) | PT2838920T (es) |
RS (1) | RS55729B1 (es) |
SG (1) | SG11201406726PA (es) |
SI (1) | SI2838920T1 (es) |
TW (1) | TWI585103B (es) |
WO (1) | WO2013158577A1 (es) |
ZA (1) | ZA201407272B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
TW201444867A (zh) * | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗tnf-抗il-17雙特異性抗體 |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
JP6505689B2 (ja) * | 2013-11-19 | 2019-04-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化b細胞活性化因子遺伝子を有する非ヒト動物 |
EA033604B1 (ru) | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
BR112018001255A2 (pt) | 2015-07-23 | 2018-09-11 | Boehringer Ingelheim International Gmbh | composto direcionado à il-23a e fator de ativação de células b (baff) e seus usos |
CN105061596B (zh) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | 人b淋巴细胞刺激因子的单克隆抗体及其应用 |
EP3735272A4 (en) * | 2018-01-05 | 2021-09-22 | Biograph 55, Inc. | COMPOSITIONS AND METHODS FOR IMMUNO CANCEROTHERAPY |
WO2022258045A1 (zh) * | 2021-06-11 | 2022-12-15 | 山东先声生物制药有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
WO2024140930A1 (en) * | 2022-12-28 | 2024-07-04 | Suzhou Transcenta Therapeutics Co., Ltd. | Bispecific binding protein comprising anti-baff antibody and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
MY169746A (en) * | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
PT1963368E (pt) | 2005-12-13 | 2012-09-14 | Lilly Co Eli | Anticorpos anti-il-17 |
WO2011141823A2 (en) * | 2010-05-14 | 2011-11-17 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
-
2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/es active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/zh not_active IP Right Cessation
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/me unknown
- 2013-04-16 RS RS20170160A patent/RS55729B1/sr unknown
- 2013-04-16 EA EA201491622A patent/EA029185B1/ru not_active IP Right Cessation
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/pt not_active Application Discontinuation
- 2013-04-16 PL PL13726321T patent/PL2838920T3/pl unknown
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en active Application Filing
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/es active Active
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/zh active Active
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 PT PT137263216T patent/PT2838920T/pt unknown
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 MX MX2014012692A patent/MX367460B/es active IP Right Grant
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/lt unknown
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/xx unknown
- 2013-04-16 SI SI201330522A patent/SI2838920T1/sl unknown
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/es active IP Right Grant
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/ko active IP Right Grant
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/ja active Active
- 2013-04-16 ES ES17153380T patent/ES2789474T3/es active Active
-
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/es unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/es unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/es unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/es unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/es unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333A1/en unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/es unknown
-
2015
- 2015-03-12 HK HK15102524.4A patent/HK1201862A1/xx not_active IP Right Cessation
-
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
-
2017
- 2017-03-21 HR HRP20170468TT patent/HRP20170468T1/hr unknown
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX367460B (es) | Anticuerpos biespecificos anti-baff-anti-il-17. | |
MX2015011957A (es) | Anticuerpos biespecificos anti-tnf-anti-il-17. | |
PH12015501994A1 (en) | Antibodies that bind il-23 | |
MX2022009875A (es) | Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes. | |
EP4036240A3 (en) | Transduction buffer | |
PH12015500294A1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
EA035160B9 (ru) | Антитела к st2 и их применение | |
EP4403570A3 (en) | Anti-il-33 antibodies and uses thereof | |
MX2016006101A (es) | Agente ligante de la il-17a y usos del mismo. | |
EA201491471A1 (ru) | Состав, содержащий антитело против ил-17 | |
MY158481A (en) | Compositions and methods for treating inflammatory disorders | |
EP3573658A4 (en) | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS | |
BR112017011961A2 (pt) | composições de polímero de polietileno de baixa névoa | |
EP4023674A3 (en) | Anti-il-22r antibodies | |
MY174711A (en) | Novel anti-fc-gamma receptor iib antibodies and uses thereof | |
EA201591334A1 (ru) | Покрывающие композиции и способы применения | |
TN2014000413A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
WO2014201400A3 (en) | Anti-factor viii antibodies or uses thereof | |
TH1401006266A (th) | แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี | |
WO2014113431A3 (en) | Methods and compositions for targeting immunoglobulins | |
UA113080C2 (xx) | Біспецифічне антитіло, яке специфічно зв'язується з il17 та baff |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |